GCM
BMRN icon

Greenland Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Greenland Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Buy
20,000
+1,900
+10% +$104K 0.14% 128
2026
Q1 		$1.02M Buy
+18,100
New +$1.06M 0.13% 136
2025
Q1 		– Sell
-3,540
Closed -$233K – 331
2024
Q4 		$233K Buy
+3,540
New +$237K 0.04% 282

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Greenland Capital Management's BMRN Position: Q2 2026 in Review

Greenland Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 10% in Q2 2026, buying an estimated $104K and bringing the position to 20,000 shares worth $1.14M. The position accounts for 0.14% of the portfolio, ranked #128.

Greenland Capital Management first reported a position in BMRN in Q4 2024 and has held it in 3 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Greenland Capital Management held 20,000 shares of BioMarin Pharmaceuticals worth $1.14M as of Q2 2026.
  • Greenland Capital Management bought 1,900 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $104K.
  • BioMarin Pharmaceuticals made up 0.14% of Greenland Capital Management's portfolio in Q2 2026, its #128 holding.
  • Greenland Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Greenland Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.